SMR 2024 | Evaluating the role of gene expression profiling in SN biopsy for melanoma

Vernon Sondak • 14 Oct 2024

SMR 2024

Melanoma Skin Cancer

MERLIN_001

Vernon Sondak, MD, Moffitt Cancer Center, Tampa, FL, explores the potential of gene expression profile testing to guide sentinel node (SN) biopsy decisions in melanoma. Based on findings the MERLIN_001 trial (NCT04759781), the test can stratify patients into high- or low-risk groups for lymph node metastasis using an eight-gene panel. Dr Sondak additionally highlights the importance of balancing risk, patient preferences, and cost-effectiveness in decision-making is emphasized for optimizing care. This interview took place at the 21st International Congress of the Society for Melanoma Research (SMR) in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.